Citius Oncology Inc

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/30/2026

Company Profile

IndustryDrug Manufacturers - Specialty & Generic

SectorHealthcare

ExchangeNASDAQ

Market Capitalization64.62 mln

Float26.09 mln

Earnings Date12/17/2026

Piotroski F-Score

4 / 9

Borderline

Relative Strength

4 / 100

Severely lagging

Debt / Equity

0.25

Very low leverage

Pre-Tax Margin

-646%

Severely loss-making

ROE

-109

Deeply negative

Altman Z-Score

-1.94

Deeply distressed

Business Description

Citius Oncology is a New Jersey-based company that develops and sells treatments for rare blood cancers. Its main product, LYMPHIR, is designed for adult patients whose cutaneous T-cell lymphoma has returned or stopped responding to previous treatment. The company operates as part of Leonard-Meron Biosciences.

Key Fundamentals

EPS-0.48

ROE-109

RPS0.08

ROIC-46.41

ROA-44.69

Interest Cover-86.40

EBITDA, mln-41.89

EV / EBITDA-2.12

EV / EBIT-1.96

Revenue, mln7.11

EV / Revenue12.52

Quote Details

Last 0.554

Change 0.0245 (4.63%)

Open 0.5274

Volume 283,271

Turnover 156,932

Average Volume 128,085

Financial Ratios

Pre-Tax Profit Margin-646

Leverage Ratio2.78

Current Ratio0.73

Price / Book2.66

Debt / Equity0.25

Price / Sales13.31

Financial Strength

Altman Z-Score-1.94

Piotroski F-Score 4 / 9

Short Ratio2.86

Short % of Float0.98

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-4.4%	19 / 100
1 Month	-43.47%	6 / 100
2 Months	-0.36%	57 / 100
6 Months	-41.37%	16 / 100
1 Year	-68.34%	12 / 100